[go: up one dir, main page]

TN2010000097A1 - Lyophilized pharmaceutical compositions - Google Patents

Lyophilized pharmaceutical compositions

Info

Publication number
TN2010000097A1
TN2010000097A1 TNP2010000097A TN2010000097A TN2010000097A1 TN 2010000097 A1 TN2010000097 A1 TN 2010000097A1 TN P2010000097 A TNP2010000097 A TN P2010000097A TN 2010000097 A TN2010000097 A TN 2010000097A TN 2010000097 A1 TN2010000097 A1 TN 2010000097A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
administered
lyophilized pharmaceutical
orally
buffer
Prior art date
Application number
TNP2010000097A
Other languages
English (en)
Inventor
Thitiwan Buranachokpaisan
Wenlei Jiang
Wei Qin Tong
Joseph Lawrence Zielinski
Jiahao Zhu
Hans-Peter Zobel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2010000097A1 publication Critical patent/TN2010000097A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TNP2010000097A 2007-09-20 2010-02-25 Lyophilized pharmaceutical compositions TN2010000097A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20
PCT/US2008/076752 WO2009039226A1 (fr) 2007-09-20 2008-09-18 Compositions pharmaceutiques lyophilisées

Publications (1)

Publication Number Publication Date
TN2010000097A1 true TN2010000097A1 (en) 2011-09-26

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000097A TN2010000097A1 (en) 2007-09-20 2010-02-25 Lyophilized pharmaceutical compositions

Country Status (20)

Country Link
US (1) US20100331387A1 (fr)
EP (1) EP2205222A1 (fr)
JP (1) JP2010540445A (fr)
KR (1) KR20100059887A (fr)
CN (1) CN101801345A (fr)
AR (1) AR068822A1 (fr)
AU (1) AU2008302273A1 (fr)
BR (1) BRPI0817118A2 (fr)
CA (1) CA2696914A1 (fr)
CL (1) CL2008002786A1 (fr)
CO (1) CO6270207A2 (fr)
EC (1) ECSP10010039A (fr)
GT (1) GT201000062A (fr)
MA (1) MA31744B1 (fr)
MX (1) MX2010002970A (fr)
PE (1) PE20090706A1 (fr)
RU (1) RU2010115262A (fr)
TN (1) TN2010000097A1 (fr)
TW (1) TW200930416A (fr)
WO (1) WO2009039226A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2743740T3 (es) * 2016-03-31 2020-02-20 Midatech Ltd Aducto de ciclodextrina-panobinostat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
NZ544920A (en) * 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
WO2006094068A2 (fr) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Inhibiteurs d’hdac favorisant l’expression des brm et diagnostics associes aux brm
WO2008086330A2 (fr) * 2007-01-10 2008-07-17 Novartis Ag Formulations d'inhibiteurs de la déacétylase
EP2491923A3 (fr) * 2007-02-15 2012-12-26 Novartis AG Combinaisons d'agents thérapeutiques pour traiter le cancer

Also Published As

Publication number Publication date
AU2008302273A1 (en) 2009-03-26
CA2696914A1 (fr) 2009-03-26
MA31744B1 (fr) 2010-10-01
RU2010115262A (ru) 2011-10-27
EP2205222A1 (fr) 2010-07-14
GT201000062A (es) 2012-03-30
ECSP10010039A (es) 2010-04-30
CN101801345A (zh) 2010-08-11
AR068822A1 (es) 2009-12-09
KR20100059887A (ko) 2010-06-04
MX2010002970A (es) 2010-04-01
US20100331387A1 (en) 2010-12-30
CL2008002786A1 (es) 2009-05-15
JP2010540445A (ja) 2010-12-24
TW200930416A (en) 2009-07-16
WO2009039226A1 (fr) 2009-03-26
PE20090706A1 (es) 2009-07-15
CO6270207A2 (es) 2011-04-20
BRPI0817118A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
WO2010039762A3 (fr) Compositions pharmaceutiques comprenant des composés d'acide boronique
WO2007123995A3 (fr) Analogue de camptothécine présentant un nouveau noyau en e 'retourné' stable à la lactone et ses procédés de préparation et d'utilisation
MX343358B (es) Tabletas de acetato de ulipristal.
EP3895699A3 (fr) Compositions pharmaceutiques contenant de l'oxyhroxyde de fer
WO2009032034A3 (fr) Forme posologique de picoplatine stabilisée
NZ588913A (en) Liver cancer drug
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
WO2007095091A3 (fr) Administration orale d'agents thérapeutiques utilisant des agonistes à jonctions serrées
WO2011159100A3 (fr) Composition pharmaceutique anticancéreuse
WO2007116102A3 (fr) Composition thérapeutique et utilisation
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
WO2011083402A3 (fr) Compositions à libération immédiate de médicaments labiles acides
WO2012042197A3 (fr) Composition pharmaceutique faiblement dosée
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
CA2688047A1 (fr) Composition de microparticules d'acide alginique biocompatibles destinees a la liberation controlee des ingredients actifs et administrees par voie intraveineuse
WO2007120838A3 (fr) Forme pharmaceutique orale, solide et à désintégration rapide, de dispersions liquides
TN2010000097A1 (en) Lyophilized pharmaceutical compositions
WO2012058276A3 (fr) Procédés et matériaux permettant la réduction de facteurs de risques multiples associés au syndrome métabolique
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
WO2008009589A3 (fr) Kit de pièces comprenant un principe actif pharmaceutique labile en milieu acide et un principe actif pharmaceutique résistant aux acides
WO2011151786A3 (fr) Formulation injectable